|
MANEA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.67899999967436E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.29449999999964E-05 |
| Normal-vs-Stage2 |
1.217110E-04 |
| Normal-vs-Stage3 |
1.89169999997851E-07 |
| Normal-vs-Stage4 |
1.57416999999604E-05 |
| Stage1-vs-Stage2 |
4.127000E-01 |
| Stage1-vs-Stage3 |
6.896200E-02 |
| Stage1-vs-Stage4 |
1.513030E-01 |
| Stage2-vs-Stage3 |
6.355600E-01 |
| Stage2-vs-Stage4 |
6.480400E-01 |
| Stage3-vs-Stage4 |
9.501600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.18589999995334E-07 |
| Normal-vs-AfricanAmerican |
1.735990E-02 |
| Normal-vs-Asian |
1.71630000000977E-06 |
| Caucasian-vs-AfricanAmerican |
3.509800E-01 |
| Caucasian-vs-Asian |
3.442400E-01 |
| AfricanAmerican-vs-Asian |
1.235620E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.8266000024787E-08 |
| Normal-vs-Female |
4.9651000000317E-06 |
| Male-vs-Female |
5.224100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.617500E-04 |
| Normal-vs-Age(41-60Yrs) |
2.15919999657643E-08 |
| Normal-vs-Age(61-80Yrs) |
2.4524999999942E-05 |
| Normal-vs-Age(81-100Yrs) |
5.383700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.936100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.729400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.663000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.878800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.137800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.179800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.099600E-01 |
| Classical-VS-Follicular |
4.295800E-01 |
| Classical-VS-Other |
1.936150E-01 |
| Classical-VS-Normal |
1.15619999996319E-06 |
| Tall-VS-Follicular |
1.340170E-01 |
| Tall-VS-Other |
3.970000E-01 |
| Tall-VS-Normal |
4.4571999999965E-05 |
| Follicular-VS-Other |
1.987800E-01 |
| Follicular-VS-Normal |
3.136100E-03 |
| Other-VS-Normal |
2.157400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.0884000003566E-07 |
| Normal-vs-N1 |
1.11089999976777E-07 |
| N0-vs-N1 |
1.225770E-01 |
|
|
